This clinical trial is focused on patients who have undergone a procedure called transcatheter aortic valve implantation (TAVI) to treat a condition known as aortic stenosis. Aortic stenosis is a narrowing of the heart’s aortic valve, which can lead to symptoms like chest pain, fatigue, and shortness of breath. The study is comparing two different durations of treatment with aspirin, a common medication used to prevent blood clots. The two forms of aspirin being studied are KARDEGIC 75 mg, which is a powder for oral solution, and ASPIRINE PROTECT 100 mg, which is a gastro-resistant tablet. Both medications are taken by mouth.

The purpose of the study is to determine if a shorter duration of aspirin therapy, lasting 3 months, is as effective as the standard 12-month therapy in preventing certain health events after the TAVI procedure. These health events include things like heart attacks, strokes, and significant bleeding. Participants in the study will be randomly assigned to either the short-term or long-term aspirin therapy group. The study will follow participants for 12 months to monitor their health and any events that occur.

Throughout the study, participants will receive regular check-ups to assess their health and any side effects from the treatment. The study aims to provide valuable information on the optimal duration of aspirin therapy for patients who have undergone TAVI, potentially improving treatment guidelines and patient outcomes in the future.